The news: Hims & Hers will stop prescribing compounded weight loss drugs to some patients after the first quarter of the year. But in other cases, Hims will still sell “clinically necessary personalized dosages of semaglutide,” CEO Andrew Dudum said during the company’s earnings call this week.

Catch up quick: The FDA recently said that Novo Nordisk’s semaglutide GLP-1 medication (marketed as Ozempic and Wegovy) is no longer in shortage. The FDA typically only allows compounded drugs to be sold when the branded forms they’re mimicking are in limited supply. This means compounded GLP-1 sellers will have a few months to take their products (which are far cheaper than their branded counterparts) off the market.

What it means for Hims: Comments from company executives on the earnings call indicate that Hims will make every effort to keep selling compounded semaglutide while complying with the FDA’s rules.